The MRTF-A/B function as oncogenes in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Myocardin-related transcription factors (MRTF-A/B), co-activators of serum response factor (SRF), are implicated in cancer cell invasion and metastasis.
• The role of MRTF-A/B in pancreatic cancer, particularly in relation to tumor progression and therapeutic resistance, remains largely unexplored.

Purpose of the Study:

• To investigate the expression and functional significance of MRTF-A/B in pancreatic cancer.
• To determine the association of MRTF-A/B with key cancer hallmarks such as epithelial-mesenchymal transition (EMT), cancer-initiating cells (CICs), and gemcitabine resistance.
• To evaluate the in vivo impact of MRTF-A/B on pancreatic tumor growth.

Main Methods:

• Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blot analysis to assess MRTF-A/B expression in pancreatic tissues and cell lines.
• In vitro studies involving overexpression of MRTF-A/B in normal and cancer pancreatic cells to evaluate effects on EMT and CIC formation.
• In vivo studies using a nude mouse xenograft model to assess the role of MRTF-A/B in tumor growth.

Main Results:

• MRTF-A/B expression was significantly altered in pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) compared to non-neoplastic tissues.
• Overexpression of MRTF-A/B induced EMT and generated stem cell-like properties in normal pancreatic cells and promoted EMT and CIC formation in pancreatic cancer cells.
• MRTF-A/B levels correlated with gemcitabine resistance in pancreatic cancer cell lines and promoted tumor growth in vivo.
• MRTF-A/B regulated microRNA expression linked to EMT and CICs.

Conclusions:

• MRTF-A/B plays a crucial role in promoting pancreatic cancer progression, including invasion, metastasis, and chemoresistance.
• MRTF-A/B contributes to the acquisition of stem cell-like properties and EMT in pancreatic cancer.
• MRTF-A/B represents a promising therapeutic target for improving treatment strategies in pancreatic cancer.